外陰癌市場 - 全球產業規模、佔有率、趨勢、機會及預測（按癌症類型、治療類型、最終用戶、地區和競爭格局分類，2021-2031年）

全球外陰癌市場預計將從 2025 年的 6.5078 億美元成長到 2031 年的 9.4052 億美元，複合年成長率為 6.33%。

該市場涵蓋用於治療外陰惡性腫瘤的診斷技術和治療性介入，例如手術、化療和免疫調節劑。推動這一市場成長的關鍵因素包括老年女性人口的增加（她們患有外陰腫瘤的風險更高）以及人類乳突病毒 (HPV) 感染率的上升（HPV 是鱗狀細胞癌的主要病因）。此外，政府大力推行的旨在促進女性健康的計劃提高了早期發現率，從而增加了需要及時治療的患者數量。

然而，由於先進生物療法的高成本以及根治性手術帶來的嚴重副作用等因素，市場面臨許多障礙。這些經濟和臨床方面的障礙可能會阻礙患者繼續治療，並限制醫療預算有限的開發中國家的市場擴張。根據美國癌症協會預測，2025年美國預計將新增約7,480個例外陰癌病例。這一數字表明，外陰癌仍然是一個沉重的疾病負擔，並凸顯了製藥企業需要致力於研發更具成本效益且耐受性良好的創新治療方法。

市場促進因素

全球外陰癌市場正因一系列新型免疫療法和標靶治療的湧現而顯著變化，為進行性或復發性疾病患者帶來了新的希望。製藥開發商正優先研發免疫查核點抑制劑，以克服傳統放射線治療的局限性，並提高複雜病例的療效。例如，在2025年6月發表於《靶向腫瘤學》（Targeted Oncology）雜誌的一篇題為「Pembrolizumab聯合治療不可切除外陰癌前景可觀」的報導中，報道了一項針對進行性不可切除鱗狀細胞癌患者的II期臨床試驗，該試驗採用Pembrolizumab、Cisplatin和放射線治療有效生物製藥的不斷湧現，透過擴大患者群體和促進高附加價值治療方法的採用，正在推動市場成長。

同時，人類乳突病毒（HPV）感染率的上升趨勢成為市場擴張的主要驅動力，也催生了對更完善的預防和治療策略的需求。由於感染率居高不下，尤其是在年輕人中，HPV相關惡性腫瘤的增加持續推動著對專業腫瘤護理的需求。美國疾病管制與預防中心（CDC）在其2025年12月發布的報告《人類乳突病毒相關癌症》中指出，據估計，HPV目前約佔所有外陰癌病例的69%。這種強烈的因果關係凸顯了進行針對性干預和嚴格篩檢計畫的迫切性。此外，美國癌症協會估計，2025年美國將有1,770名女性死於外陰癌，這更強調了持續開發先進的診斷和治療方案的重要性。

市場挑戰

生物療法的高昂成本是全球外陰癌市場擴張的主要障礙。這些藥物的高價結構造成了巨大的經濟壁壘，尤其是在醫療預算有限的發展中地區。當先進的治療方法仍然難以負擔時，市場滲透率就會受到嚴重阻礙，製造商也無法在這些地區實現最大化收益。因此，該市場未能廣泛普及，成長主要局限於富裕人群，而無法滿足更廣泛的全球患者群體的需求。

這種經濟限制因素因根治性手術相關的臨床障礙而進一步加劇，這些手術往往伴隨嚴重的副作用風險。這些因素共同導致疾病盛行率與現有治療性介入的利用率之間存在脫節。死亡率數據凸顯了這種差距，顯示目前的市場機制不足以減輕疾病負擔。根據美國癌症協會預測，到2025年，外陰癌預計將在美國造成約1,770例死亡。這項統計數據表明，儘管技術已經成熟，但經濟和臨床障礙仍然阻礙著治療的成功，並直接抑制了市場成長。

市場趨勢

全球外陰癌市場在哨兵淋巴結（SLN）定位和切片檢查通訊協定取得了顯著進展，正從傳統的染料標記技術過渡到螢光引導技術，從而減少手術併發症。臨床醫生擴大採用靛氰綠（ICG）示蹤劑來提高淋巴結分期的準確性，從而最大限度地減少與淋巴結清除術相關的淋巴水腫的發生率。這一轉變得到了令人信服的臨床數據的支持。根據發表在2025年5月《醫師周刊》（Physician's Weekly）上的報導“靛氰綠在外陰SLN檢測中與雙重示踪劑效果相當”，一項系統評價發現，使用靛氰綠進行哨兵淋巴結檢測的患者檢出率高達88%，證明其是一種高效且創傷性更小的標準標準。

同時，基因組分析在個人化治療方案製定中的應用正在重塑治療格局，尤其是在HPV非依賴性腫瘤領域，這類腫瘤歷來缺乏標靶治療方案。臨床醫生正將次世代定序納入常規診斷流程，以識別具有治療價值的體細胞突變，並促進患者分層，從而為新興的精準醫療療法提供依據。這一趨勢也得到了近期分子特徵分析研究的支持。根據發表於2024年12月《國際婦科腫瘤學雜誌》（International Journal of Gynecological Cancer）的一篇題為“人類乳突病毒非依賴性外陰浸潤性鱗狀細胞癌的分子和微環境特徵”的論文，靶向定序發現，在68%的研究病例中存在影響TP53的復發性生物標記治療了顯性生物標記的重要潛力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球外陰癌市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 癌症類型（外陰鱗狀細胞癌、外陰黑色素瘤、腺癌、基底細胞癌）
  • 依治療方法（化療、手術、雷射手術、切除術、外陰陰道分離、根治性外陰切除術、放射性外陰切除術、生物治療）
  • 依最終使用者（醫院/診所、研究/學術機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章 北美外陰癌市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲外陰癌市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區外陰癌市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東與非洲外陰癌市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲外陰癌市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球外陰癌市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Vulvar Cancer Market is projected to increase from USD 650.78 Million in 2025 to USD 940.52 Million by 2031, registering a CAGR of 6.33%. This market comprises diagnostic technologies and therapeutic interventions, such as surgery, chemotherapy, and immunomodulators, designed to manage vulvar malignancies. Key factors driving this growth include an aging female population increasingly prone to vulvar neoplasia and a rising incidence of Human Papillomavirus infections, which are a primary cause of squamous cell carcinomas. Additionally, strong government programs focused on improving women's health are boosting early detection rates, thereby increasing the number of patients requiring timely medical treatment.

However, the market faces significant hurdles due to the high cost of advanced biologic therapies and the severe side effects often associated with radical surgical procedures. These financial and clinical barriers can discourage patient compliance and restrict market reach in developing nations with limited healthcare budgets. According to the American Cancer Society, approximately 7,480 new cases of vulvar cancer are expected to be diagnosed in the United States in 2025. This figure highlights the persistent burden of the disease, underscoring the need for manufacturers to focus on developing cost-effective and well-tolerated treatment innovations.

Market Driver

The Global Vulvar Cancer Market is being significantly transformed by a strong pipeline of novel immunotherapies and targeted agents, providing new prospects for patients with advanced or recurrent conditions. Pharmaceutical developers are prioritizing immune checkpoint inhibitors to surpass the limitations of traditional chemoradiation, thereby improving efficacy for complex cases. For example, Targeted Oncology reported in June 2025, in the article 'Pembrolizumab Combo Promising for Unresectable Vulvar Cancer', that a recent phase 2 clinical trial showed a 75% objective response rate in patients with locally advanced, unresectable squamous cell carcinoma when treated with a combination of pembrolizumab, cisplatin, and radiation. This rise in effective biologic agents is fueling market growth by widening the eligible patient base and promoting the adoption of premium therapeutic regimens.

Simultaneously, the increasing prevalence of Human Papillomavirus (HPV) infections acts as a major catalyst for market expansion, creating a need for improved preventative and therapeutic strategies. As infection rates endure, particularly among younger populations, the rise in HPV-linked malignancies continues to elevate the demand for specialized oncological care. The Centers for Disease Control and Prevention (CDC) noted in its December 2025 report 'Cancers Associated with Human Papillomavirus' that HPV is now estimated to cause approximately 69% of all vulvar cancers. This strong causal link emphasizes the urgent need for targeted interventions and strict screening programs; furthermore, the American Cancer Society estimates that 1,770 women in the United States will die from vulvar cancer in 2025, reinforcing the critical necessity for the continued development of advanced diagnostic and therapeutic solutions.

Market Challenge

The prohibitive costs associated with biologic therapies represent a major barrier to the expansion of the Global Vulvar Cancer Market. The high pricing structures of these agents create substantial economic obstacles, particularly in developing regions where healthcare budgets are constrained. When advanced treatments remain financially inaccessible, market penetration is severely curtailed, preventing manufacturers from optimizing revenue within these demographics. Consequently, the market struggles to achieve broad adoption, limiting its growth primarily to affluent segments rather than addressing the needs of the wider global patient population.

This economic restriction is compounded by clinical deterrents associated with radical surgical procedures, which frequently carry risks of severe side effects. Collectively, these factors create a gap between the prevalence of the disease and the utilization of available therapeutic interventions. This disparity is underscored by mortality data suggesting that current market mechanisms are not fully alleviating the disease burden. According to the American Cancer Society, approximately 1,770 deaths were projected to result from vulvar cancer in the United States in 2025. This statistic indicates that despite available technologies, economic and clinical hurdles continue to impede the successful delivery of care, directly hampering market growth.

Market Trends

The Global Vulvar Cancer Market is experiencing significant advancement in sentinel lymph node (SLN) mapping and biopsy protocols, shifting from traditional dye-based methods to fluorescence-guided techniques that reduce surgical morbidity. Clinicians are increasingly adopting indocyanine green (ICG) tracers to enhance the precision of nodal staging, thereby minimizing the incidence of lymphedema associated with complete lymphadenectomy. This transition is supported by compelling clinical data; according to Physician's Weekly in May 2025, in the article 'Indocyanine Green Matches Dual Tracers in Vulvar SLN Detection', a systematic review found that the per-patient sentinel lymph node detection rate for indocyanine green was 88%, proving it to be a highly effective and less invasive alternative to standard radiotracers.

Concurrently, the implementation of genomic profiling for personalized treatment plans is reshaping the therapeutic landscape, particularly for HPV-independent tumors which have historically lacked targeted options. Medical centers are incorporating next-generation sequencing into routine diagnostic workflows to identify actionable somatic mutations, facilitating the stratification of patients for emerging precision medicine therapies. This trend is substantiated by recent molecular characterization efforts; as reported by the International Journal of Gynecological Cancer in December 2024, in the article 'Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva', targeted sequencing revealed recurrent somatic mutations affecting TP53 in 68% of the studied cases, highlighting its potential as a critical biomarker for therapeutic selection.

Key Market Players

• Merck & Co. Inc.
• Sanofi SA
• Novartis AG
• Astellas Pharma Inc.
• Pfizer Inc.
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company

Report Scope

In this report, the Global Vulvar Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvar Cancer Market, By Cancer Type

• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma

Vulvar Cancer Market, By Treatment Type

• Chemotherapy
• Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Vulvectomy
• Biologic Therapy

Vulvar Cancer Market, By End-User

• Hospitals & Clinics
• Research & Academic Institutes
• Others

Vulvar Cancer Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Vulvar Cancer Market.

Available Customizations:

Global Vulvar Cancer Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Vulvar Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma)
  • 5.2.2. By Treatment Type (Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Vulvectomy, Biologic Therapy)
  • 5.2.3. By End-User (Hospitals & Clinics, Research & Academic Institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Vulvar Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Vulvar Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Vulvar Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Vulvar Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By End-User

7. Europe Vulvar Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Vulvar Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Vulvar Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Vulvar Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Vulvar Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Vulvar Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By End-User

8. Asia Pacific Vulvar Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Vulvar Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Vulvar Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Vulvar Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Vulvar Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Vulvar Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Vulvar Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Vulvar Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Vulvar Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Vulvar Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By End-User

10. South America Vulvar Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Vulvar Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Vulvar Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Vulvar Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Vulvar Cancer Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co. Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Sanofi SA
• 15.3. Novartis AG
• 15.4. Astellas Pharma Inc.
• 15.5. Pfizer Inc.
• 15.6. Abbott Laboratories
• 15.7. Bristol-Myers Squibb Company
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. F. Hoffmann-La Roche Ltd
• 15.10. Eli Lilly and Company

16. Strategic Recommendations

17. About Us & Disclaimer